Quantcast
Last updated on April 18, 2014 at 10:39 EDT

Latest Cell Therapeutics Inc. Stories

2013-08-19 04:20:35

SEATTLE, Aug. 19, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the Transparency Commission (Commission de la Transparence or CT) of the French National Health Authority (Haute Autorite de Sante or HAS) has granted market access for the medicinal product PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive...

2013-07-31 16:27:50

- Conference call scheduled today at 4:30 p.m. Eastern time - SEATTLE, July 31, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the second quarter and six months ended June 30, 2013. "The second quarter was highlighted by the substantial progress we made in our reimbursement discussions for PIXUVRI(®) (pixantrone) in Europe, specifically in the UK and Italy," said James Bianco, M.D., President and CEO of CTI. "In...

2013-07-24 04:22:01

SEATTLE, July 24, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that Daniel D. Von Hoff, M.D., F.A.C.P, a leading medical oncologist who has been the lead investigator in the development of important oncology therapeutics, will serve as Chairman of CTI's Scientific Advisory Board. The purpose of the Scientific Advisory Board will be to assist management in the strategic development of its oncology portfolio and clinical trial design; work...

2013-07-24 00:20:28

- Conference call and webcast at 4:30 p.m. Eastern Time - SEATTLE, July 24, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its second quarter financial results on Wednesday, July 31, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m....

2013-07-17 08:26:50

LONDON, July 17, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Tuesday, July 16, 2013, shares in biotechnology companies ended mostly lower, tracking losses in the broader market. The major movers in the industry included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Medivation Inc. (NASDAQ: MDVN), and Cell Therapeutics Inc. (NASDAQ: CTIC). AAAResearchReports.com has...

2013-07-08 04:21:44

SEATTLE, July 8, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Company has been granted market access by the Italian Medicines Agency (AIFA) for the medicinal product PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy). Pixantrone has been classified by...

2013-07-08 04:21:36

SEATTLE, July 8, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, has notified CTI and issued a statement on their website stating that CTI's patient access scheme has been approved by the Department of Health and the appeal stage of this appraisal topic is suspended. The draft final appraisal...

2013-07-03 04:20:34

SEATTLE, July 3, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013. The article reviews the preclinical pharmacology and pharmacokinetics in addition to the safety and efficacy results from the Phase 1 and 2 clinical studies of...

2013-07-01 04:20:31

( ) SEATTLE, July 1, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, issued a second draft guidance on the use of PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive...

2013-06-28 20:22:47

SEATTLE, June 28, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC and MTA: CTIC) today announced the resignation of Steven E. Benner, M.D., M.H.S., Senior Vice President, Chief Medical Officer and Chief Compliance Officer for personal reasons. Nancy Boman, M.D., Ph.D., Senior Vice President, Clinical Development and Regulatory Affairs, is expected to assume interim responsibility for the oversight of CTI's ongoing and planned clinical trials of compounds for the...